Arkolith/Insider Trading/INZY/Form 4

Bolte Axel

Chief Executive Officer, DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed Jun 25, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 24, 2021Option exercise(M)67K$0.98$65K258K
Jun 24, 2021Sell(S)67K—$0191K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 24, 2021Option exercise(M)67K—$0100K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-21-043205) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML